Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split REDWOOD CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of
How this was made
The 30-second read
Why it matters
The reverse split aims to boost share price and maintain Nasdaq listing compliance, but may reduce liquidity and trigger short‑term volatility.
Market read
The split is a corporate action that could affect short‑term price dynamics and compliance status.
What to watch
Potential impact on warrant and option exercise terms could affect derivative positions.
Background
Jasper Therapeutics is a clinical‑stage biotech listed on Nasdaq under JSPR.
Ticker impact
Jasper Therapeutics filed an 8‑K announcing a 1‑for‑30 reverse stock split effective November 6, 2026.
likely downward pressure as the market prices in reduced liquidity and uncertainty around post‑split price stability
Reverse splits are often viewed unfavorably by investors; the announcement is new and will affect trading on the effective date.
Market effects
May signal compliance concerns for other small‑cap biotech firms on Nasdaq
Limited to US Nasdaq biotech segment
Low
Counterpoint
Some investors may view the split as a chance to buy at a higher price floor if liquidity improves post‑split.
Key entities
- companyJasper Therapeutics, Inc.
Issuer of the reverse stock split.
